INTENSITY THERAPEUTICS, INC. — Investor Relations & Filings

Intensity Therapeutics, Inc. is a late-stage clinical company developing a novel intratumoral approach to treat solid tumor cancers. Its proprietary DfuseRx℠ platform technology facilitates the direct injection of therapeutic agents into tumors, enabling high drug absorption and dispersion. This "treat locally, act globally" method is designed to kill cancer cells in the injected tumor and simultaneously stimulate a systemic, personalized T-cell immune response against both the primary tumor and distant metastases. The company's lead product candidate, INT230-6, is advancing in late-stage clinical trials for multiple cancers, including sarcoma and breast cancer. The goal is to extend survival for patients with metastatic disease and prevent recurrence in presurgical settings.